BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31482509)

  • 21. Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands.
    Alfian SD; Worawutputtapong P; Schuiling-Veninga CCM; van der Schans J; Bos JHJ; Hak E; Denig P
    Curr Med Res Opin; 2018 Jun; 34(6):1013-1019. PubMed ID: 29292657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
    Fralick M; Chen SK; Patorno E; Kim SC
    Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.
    Grimes RT; Bennett K; Tilson L; Usher C; Smith SM; Henman MC
    Br J Clin Pharmacol; 2015 Jun; 79(6):1000-9. PubMed ID: 25521800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of statin use and long-term adherence and persistence among older adults with diabetes.
    Ofori-Asenso R; Ilomäki J; Tacey M; Zomer E; Curtis AJ; Bell JS; Zoungas S; Liew D
    J Diabetes; 2018 Sep; 10(9):699-707. PubMed ID: 29658177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
    Menne J; Dumann E; Haller H; Schmidt BMW
    PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year adherence to oral antihyperglycemic medication and risk prediction of patient outcomes for adults with diabetes mellitus: An observational study.
    Huber CA; Rapold R; Brüngger B; Reich O; Rosemann T
    Medicine (Baltimore); 2016 Jun; 95(26):e3994. PubMed ID: 27368004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas.
    Bell KF; Cappell K; Liang M; Kong AM
    Am Health Drug Benefits; 2017 Jun; 10(4):165-174. PubMed ID: 28794821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI.
    Ye X; Qian C; Liu J; St Peter WL
    Pharmacotherapy; 2013 Oct; 33(10):1062-70. PubMed ID: 23798059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in health outcomes associated with initial adherence to oral antidiabetes medications among veterans with uncomplicated Type 2 diabetes: a 5-year survival analysis.
    Gatwood JD; Chisholm-Burns M; Davis R; Thomas F; Potukuchi P; Hung A; Kovesdy CP
    Diabet Med; 2018 Nov; 35(11):1571-1579. PubMed ID: 29978496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of Dual Health Care System Use for Obtaining Prescription Medications on Nonadherence in Veterans With Type 2 Diabetes.
    Taber DJ; Ward R; Axon RN; Walker RJ; Egede LE; Gebregziabher M
    Ann Pharmacother; 2019 Jul; 53(7):675-682. PubMed ID: 30724092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.
    Morton JI; Ilomӓki J; Magliano DJ; Shaw JE
    Diabetologia; 2021 Feb; 64(2):349-360. PubMed ID: 33078206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Persistent Medication Adherence and Compliance with Lifestyle Recommendations on Major Cardiovascular Events and One-Year Mortality in Patients with Type 2 Diabetes and Advanced Stages of Atherosclerosis: Results From a Prospective Cohort Study.
    Shalaeva EV; Bano A; Kasimov U; Janabaev B; Laimer M; Saner H
    Glob Heart; 2023; 18(1):61. PubMed ID: 37928361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence, persistence, and treatment discontinuation with sitagliptin compared with sulfonylureas as add-ons to metformin: A retrospective cohort database study.
    Bloomgarden ZT; Tunceli K; Liu J; Brodovicz KG; Mavros P; Engel SS; Radican L; Chen Y; Rajpathak S; Qiu Y; Brudi P; Fonseca V
    J Diabetes; 2017 Jul; 9(7):677-688. PubMed ID: 27531167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
    Zhao B; Shen J; Zhao J; Pan H
    J Diabetes Investig; 2021 Aug; 12(8):1400-1407. PubMed ID: 33325646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to metformin and the onset of rheumatoid arthritis: a population-based cohort study.
    Naffaa ME; Rosenberg V; Watad A; Tiosano S; Yavne Y; Chodick G; Amital H; Shalev V
    Scand J Rheumatol; 2020 May; 49(3):173-180. PubMed ID: 32208872
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus.
    Doğruel H; Atlım HT; Aydemir M; Yılmaz N; Sarı R
    Ir J Med Sci; 2023 Oct; 192(5):2189-2195. PubMed ID: 36580225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence of patients with type 2 diabetes mellitus to medications: the role of risk preferences.
    Simon-Tuval T; Shmueli A; Harman-Boehm I
    Curr Med Res Opin; 2018 Feb; 34(2):345-351. PubMed ID: 29069921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.